A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global overview and analysis of drug development, detailed product and pipeline analysis by market segment, drug class, and stage of development, and detailed product profiles for key marketed and late-stage products is included in the study. Also included are time-sensitive details such as new product launch timelines, cardiovascular outcomes trials timelines, and patent expirations.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Recent Market DevelopmentsRecent Market Developments (continued)New Market OpportunitiesCompanies to WatchMethodology and ScopeMethodology and ScopeIntroductionIntroductionMarket BackgroundDisease Classification and Diagnostics—Type 2 DiabetesDisease Classification and Diagnostics—Type 1 DiabetesDiagnostic CriteriaMarket Segmentation Market Segmentation (continued) Market Segmentation (continued) Market Segmentation (continued) Market Segmentation (continued)Competitive LandscapeTimeline of New Product LaunchesCompetitive Landscape—Insulin Segment, Count of Marketed and Pipeline ProductsCompetitive Landscape—Insulin Segment, Marketed and Pipeline ProductsMarketed Product Analysis—Insulin SegmentMarketed Product Analysis—Insulin Segment (continued)Pipeline Analysis—Insulin Segment, Products in Late-stage Clinical DevelopmentPipeline Analysis—Insulin Segment, Products in Late-stage Clinical Development (continued)Pipeline Analysis—Insulin Segment, Products in Mid-stage Clinical DevelopmentPipeline Analysis—Insulin Segment, Products in Early-stage Clinical DevelopmentPipeline Analysis—Insulin Segment, Products in Early-stage Clinical Development (continued)Competitive Landscape—Non-insulin Segment, Count of Marketed and Pipeline ProductsCompetitive Landscape—Non-insulin Segment, Late-stage and Marketed ProductsCompetitive Landscape—Non-insulin Segment, Early- and Mid-stage Pipeline ProductsMarketed Product Analysis—Non-insulin SegmentMarketed Product Analysis—Non-insulin Segment (continued)Marketed Product Analysis—Non-insulin Segment (continued)Marketed Product Analysis—Non-insulin Segment (continued)Marketed Product Analysis—Non-insulin Segment (continued)Pipeline Analysis—Non-insulin Segment, Products in Late-stage Clinical DevelopmentPipeline Analysis—Non-insulin Segment Products in Late-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment Products in Late-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical DevelopmentPipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical DevelopmentPipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)Patent ExpirationsPatent Expirations (continued)Cardiovascular Outcomes Trials TimelineComparative Product Profiles of Promising Late-stage CandidatesComparative Efficacy AnalysisComparative Efficacy Analysis (continued)Comparative Efficacy Analysis DiscussionProduct ProfilesMarketed Product Profiles—Rapid-acting InsulinMarketed Product Profiles—Intermediate-acting/Pre-mix InsulinMarketed Product Profiles—Basal InsulinMarketed Product Profiles—DPP-4 InhibitorsMarketed Product Profiles—DPP-4 Inhibitors (continued)Marketed Product Profiles—GLP-1 Agonists/AnalogsMarketed Product Profiles—GLP-1 Agonists/Analogs (continued)Marketed Product Profiles—SGLT2 InhibitorsConclusions and RecommendationsConclusions and RecommendationsThe Last Word—3 Big PredictionsThe Last Word—DiscussionThe Last Word—Discussion (continued)The Last Word—Discussion (continued)Legal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation Excellence




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 07-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 17-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.